Get the Stockscreener App
2.91
3.57%
-0.17
Climb Bio Inc stock is traded at $2.91, with a volume of 17,094.
It is down -3.57% in the last 24 hours and down -38.12% over the past month.
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.
See More
Previous Close:
$3.08
Open:
$3.09
24h Volume:
17,094
Relative Volume:
0.11
Market Cap:
$207.05M
Revenue:
-
Net Income/Loss:
$-64.20M
P/E Ratio:
-
EPS:
-
Net Cash Flow:
$57,000
1W Performance:
-7.04%
1M Performance:
-38.12%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$2.95
$3.09
1-Week Range:
$2.96
$3.355
52-Week Range:
$2.96
$5.47
Climb Bio Inc Stock (CLYM) Company Profile
Name
Climb Bio Inc
Sector
Industry
Phone
1-866-857-2596
Address
20 WILLIAM STREET, WELLESLEY HILLS
Compare CLYM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| CLYM | 2.95 | 207.05M | 0 | -64.20M | 57,000 | 0.00 |
| VRTX | 447.12 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 740.36 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 590.00 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.10 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.41 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Climb Bio Inc Stock (CLYM) Latest News
Are Wall Street Analysts Predicting KKR Stock Will Climb or Sink? - MSN
Deep Track Capital, LP Reduces Stake in Climb Bio Inc - GuruFocus.com
Are Business Services Stocks Lagging Climb Global Solutions, Inc. (CLMB) This Year? - Yahoo Finance
Sri Lankan Stocks Climb, Information Technology Leads The Way - Finimize
Climb Bio Inc. Shifts Focus to Immune-Mediated Diseases - TipRanks
Climb Bio Reports Third Quarter 2024 Financial Results and Business Highlights - GlobeNewswire
iBio Reports Fiscal First Quarter 2025 Financial Results - The Manila Times
Climb Bio Secures FDA Clearance for SLE Drug Trial, Reports $217.9M Cash Position | CLYM Stock News - StockTitan
Climb Bio Appoints Douglas E. Williams, Ph.D., as Chair of the Board - GlobeNewswire
Climb Bio Appoints Biotech Veteran Douglas Williams as Board Chair, Strengthens Leadership | CLYM Stock News - StockTitan
Sales climb for EcoSynthetix Inc. in Q3 - Pulp & Paper Canada
Climb Bio to Present at Upcoming Investor Conferences - GlobeNewswire
Nasdaq Futures Climb on Upbeat Alphabet Results, U.S. GDP Data and More Big Tech Earnings on Tap - MSN
Humic Acid Market Set to Climb to USD 1.63 Billion by 2030 - openPR
ABVC BioPharma receives $50,000 in incremental licensing fees, shares climb - MSN
Tevogen Bio (TVGN) Sees Major Stock Surge After Key AI Move - Stocks Telegraph
Interpublic Group Of Cos., Inc. (IPG): Worth A Small Bite At $32.03 - Stocks Register
Why Lamb Weston Stock Was Climbing Today - Yahoo Finance
Big Bank Stocks Climb. 3 Stocks to Consider Adding to Your Portfolio. - Yahoo Finance
Merck & Co’s Clesrovimab Has Beyfortus Hill To Climb In RSV - Citeline News & Insights
Treasury Yields Climb as Strong Data Sow Doubt on Fed Rate Cuts - Yahoo Finance
Mortgage Demand Sees Sharpest Weekly Drop Since April 2020 As Rates Climb Above 6.5% - Yahoo Finance
Korean growth stocks climb after rate cut - 코리아타임스
Vale Achieves Six-Year High in Iron Ore Output, Copper and Nickel Production Also Climb - Yahoo Finance
European Wax Center Continues to Climb in Franchise Times' Top 400 Ranking - Yahoo Finance
US Mortgage Rates Climb to 6.52%, Highest Since Early August - Yahoo Finance
What You Need to Know Ahead of Bio-Techne's Earnings Release - TradingView
Stocks of B. Riley Financial Inc (RILY) are poised to climb above their peers - SETE News
Climb Bio to Provide Budoprutug Development Strategy and Corporate Update at Virtual Investor Event - The Manila Times
‘Retirement super pot’ holders pay themselves around £3m each in a year - Yahoo Finance UK
Climb Bio to present kidney disease treatment study By Investing.com - Investing.com Australia
Climb Bio Announces Abstract Selected for Presentation at the American Society of Nephrology Kidney Week 2024 - GlobeNewswire
Climb Bio to present kidney disease treatment study - Investing.com India
Climb Bio Announces Abstract Selected for Presentation at the American Society of Nephrology - The Bakersfield Californian
A stock that deserves closer examination: Climb Bio Inc. (CLYM) - US Post News
Climb Global (CLMB) Surged on Strong Results - Yahoo Finance
Quarterly IPOs Climb Back Above $1bn - Scrip
US 30-Year Mortgage Rate Climbs by Most in More Than a Year - Yahoo Finance
Climb Global (CLMB) Moves 7.0% Higher: Will This Strength Last? - Yahoo Finance
FDA Oncology Approvals Accelerate as Global Cancer Rates Set to Climb 77% - Baystreet.ca
Climb Bio to Present at William Blair’s Upcoming Conference Event on Transforming Autoimmune Diseases by Targeting CD19 - ForexTV.com
Climb Bio to Present at William Blair’s Upcoming Conference - GlobeNewswire
Climb Bio to Present at William Blair's Upcoming Conference Event on Transforming Autoimmune Diseases by Targeting CD19 - The Manila Times
Intumescent Coatings Market Size to Climb to USD 2.4 - GlobeNewswire
Intumescent Coatings Market Size to Climb to USD 2.4 billion by 2034 with a 7.4% CAGR, Supported by Steel Fabrication Fireproofing Demand | States Transparency Market Research, Inc. - Yahoo Finance
First Merchants Corporation to Report Third Quarter 2024 Financial Results, Host Conference Call and Webcast - The Manila Times
Climb Bio to Host Virtual Investor Event on October 15, 2024 - GlobeNewswire
Climb Bio Inc Stock (CLYM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Climb Bio Inc Stock (CLYM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Morisset Valerie | EVP, R&D AND CSO |
Jul 22 '24 |
Sale |
8.03 |
69,005 |
554,170 |
31,317 |
| Morisset Valerie | EVP, R&D AND CSO |
Jul 19 '24 |
Sale |
7.21 |
60,201 |
434,325 |
100,322 |
| Morisset Valerie | EVP, R&D AND CSO |
Jul 18 '24 |
Sale |
6.93 |
38,576 |
267,332 |
160,523 |
| Morisset Valerie | EVP, R&D AND CSO |
Jul 17 '24 |
Sale |
6.91 |
3,207 |
22,160 |
199,099 |
| Morisset Valerie | EVP, R&D AND CSO |
Jul 16 '24 |
Sale |
7.13 |
50,000 |
356,500 |
202,306 |
| Morisset Valerie | EVP, R&D AND CSO |
Jul 12 '24 |
Sale |
7.07 |
50,000 |
353,500 |
294,683 |
| Morisset Valerie | EVP, R&D AND CSO |
Jul 15 '24 |
Sale |
7.01 |
42,377 |
297,063 |
252,306 |
| Morisset Valerie | EVP, R&D AND CSO |
Jul 11 '24 |
Sale |
7.11 |
50,000 |
355,500 |
344,683 |
| Morisset Valerie | EVP, R&D AND CSO |
Jul 10 '24 |
Sale |
6.83 |
50,000 |
341,500 |
394,683 |
| Morisset Valerie | EVP, R&D AND CSO |
Jul 09 '24 |
Sale |
6.66 |
5,931 |
39,500 |
444,683 |
0.42%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):